Compare Stocks: ARWR, RVMD, NTRA, and BIIB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$88.09 +0.5%	$79.97	$15.81 ▼ $95.49	$12.43B	1.27	2.43 million shs	371,592 shs
BIIB Biogen	$207.14 -0.4%	$202.33	$127.71 ▼ $219.72	$30.63B	0.17	1.27 million shs	262,642 shs
NTRA Natera	$314.39 -2.4%	$254.03	$149.38 ▼ $326.03	$45.04B	1.51	1.36 million shs	1.19 million shs
RVMD Revolution Medicines	$205.45 +0.1%	$176.66	$34.14 ▼ $208.76	$44.04B	1.39	3.12 million shs	878,094 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	+3.54%	+14.73%	+12.75%	+433.80%
BIIB Biogen	0.00%	+2.46%	+4.41%	+5.05%	+59.13%
NTRA Natera	0.00%	+20.29%	+19.32%	+61.75%	+111.98%
RVMD Revolution Medicines	0.00%	+9.40%	+9.78%	+42.32%	+486.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$88.09 +0.5%	$79.97	$15.81 ▼ $95.49	$12.43B	1.27	2.43 million shs	371,592 shs
BIIB Biogen	$207.14 -0.4%	$202.33	$127.71 ▼ $219.72	$30.63B	0.17	1.27 million shs	262,642 shs
NTRA Natera	$314.39 -2.4%	$254.03	$149.38 ▼ $326.03	$45.04B	1.51	1.36 million shs	1.19 million shs
RVMD Revolution Medicines	$205.45 +0.1%	$176.66	$34.14 ▼ $208.76	$44.04B	1.39	3.12 million shs	878,094 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	+3.54%	+14.73%	+12.75%	+433.80%
BIIB Biogen	0.00%	+2.46%	+4.41%	+5.05%	+59.13%
NTRA Natera	0.00%	+20.29%	+19.32%	+61.75%	+111.98%
RVMD Revolution Medicines	0.00%	+9.40%	+9.78%	+42.32%	+486.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.62	Moderate Buy	$97.33	10.50% Upside
BIIB Biogen	2.56	Moderate Buy	$224.61	8.43% Upside
NTRA Natera	2.77	Moderate Buy	$301.90	-3.97% Downside
RVMD Revolution Medicines	2.91	Moderate Buy	$160.68	-21.79% Downside

Current Analyst Ratings Breakdown

Latest ARWR, RVMD, NTRA, and BIIB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	NTRA Natera	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$355.00
8/10/2026	RVMD Revolution Medicines	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$220.00
8/7/2026	NTRA Natera	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$325.00 ➝ $340.00
8/7/2026	NTRA Natera	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$275.00 ➝ $350.00
8/7/2026	NTRA Natera	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$348.00
8/7/2026	NTRA Natera	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$375.00
8/7/2026	NTRA Natera	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$220.00 ➝ $284.00
8/7/2026	NTRA Natera	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$300.00 ➝ $315.00
8/7/2026	NTRA Natera	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$290.00 ➝ $320.00
8/7/2026	NTRA Natera	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$330.00
8/7/2026	NTRA Natera	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$340.00

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$669.50M	18.53	$0.12 per share	734.09	$3.64 per share	24.20
BIIB Biogen	$9.89B	3.09	$22.54 per share	9.19	$124.45 per share	1.66
NTRA Natera	$2.71B	16.63	N/A	N/A	$12.38 per share	25.40
RVMD Revolution Medicines	$11.58M	3,802.78	N/A	N/A	$8.44 per share	24.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.25	N/A	N/A	N/A	-47.79%	-60.06%	-17.37%	N/A
BIIB Biogen	$1.29B	$5.65	36.69	12.64	6.42	8.32%	11.18%	6.88%	10/29/2026 (Estimated)
NTRA Natera	-$208.16M	-$1.36	N/A	N/A	N/A	-7.11%	-11.82%	-8.19%	N/A
RVMD Revolution Medicines	-$1.13B	-$8.82	N/A	N/A	N/A	N/A	-88.20%	-57.85%	N/A

Latest ARWR, RVMD, NTRA, and BIIB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	NTRA Natera	-$0.4939	-$0.47	+$0.0239	-$0.47	$661.24 million	$752.75 million
8/5/2026	Q2 2026	RVMD Revolution Medicines	-$2.04	-$3.06	-$1.02	-$3.06	$1.77 million	N/A
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.23	-$1.36	-$0.13	-$1.36	$44.17 million	$75.25 million
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	1.77	5.90	5.90
BIIB Biogen	0.39	1.87	1.26
NTRA Natera	N/A	2.96	2.83
RVMD Revolution Medicines	0.40	11.38	11.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BIIB Biogen	87.93%
NTRA Natera	99.90%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	3.60%
BIIB Biogen	0.25%
NTRA Natera	5.05%
RVMD Revolution Medicines	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	140.86 million	135.79 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
NTRA Natera	6,140	143.22 million	135.98 million	Optionable
RVMD Revolution Medicines	250	214.34 million	198.05 million	Optionable

ARWR, RVMD, NTRA, and BIIB Headlines

Recent News About These Companies

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

August 10 at 6:00 AM | businesswire.com

Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)

August 9 at 3:02 PM | theglobeandmail.com

Assenagon Asset Management S.A. Buys Shares of 200,486 Revolution Medicines, Inc. $RVMD

August 9 at 3:27 AM | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $240.00

August 9 at 2:48 AM | americanbankingnews.com

Sei Investments Co. Cuts Holdings in Revolution Medicines, Inc. $RVMD

August 8 at 4:39 AM | marketbeat.com

'We're excited and ready to go': Fast-growing Revolution Medicines preps potential launch of blockbuster pancreatic cancer drug

August 7 at 7:43 PM | bizjournals.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)

August 7 at 7:43 PM | theglobeandmail.com

High Risk, High Reward: Inside The Revolution Medicines Bull Case

August 7 at 5:00 AM | seekingalpha.com

RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View

August 6, 2026 | zacks.com

Needham & Company LLC Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $240.00

August 6, 2026 | marketbeat.com

Quantinno Capital Management LP Boosts Stake in Revolution Medicines, Inc. $RVMD

August 6, 2026 | marketbeat.com

Revolution Medicines Q2 Earnings Call Highlights

August 5, 2026 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Announces Earnings Results

August 5, 2026 | marketbeat.com

Revolution Medicines Q2 Net Loss Widens

August 5, 2026 | finance.yahoo.com

Revolution Medicines updates 2026 GAAP operating expenses to $2.1B-$2.2B while preparing potential daraxonrasib launch

August 5, 2026 | seekingalpha.com

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

August 5, 2026 | globenewswire.com

Revolution Medicines (NASDAQ:RVMD) Sets New 1-Year High - Time to Buy?

August 5, 2026 | marketbeat.com

Amundi Buys 118,493 Shares of Revolution Medicines, Inc. $RVMD

August 5, 2026 | marketbeat.com

Royal Bank of Canada Sells 131,978 Shares of Revolution Medicines, Inc. $RVMD

August 4, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Decreases Position in Revolution Medicines, Inc. $RVMD

August 3, 2026 | marketbeat.com

Revolution Medicines, Inc. $RVMD Shares Sold by Defilade Capital Management L.P.

August 3, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ARWR, RVMD, NTRA, and BIIB Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$88.09 +0.44 (+0.50%)

As of 01:57 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Biogen NASDAQ:BIIB

$207.14 -0.80 (-0.39%)

As of 01:57 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Natera NASDAQ:NTRA

$314.39 -7.71 (-2.39%)

As of 01:57 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Revolution Medicines NASDAQ:RVMD

$205.45 +0.30 (+0.15%)

As of 01:57 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARWR, RVMD, NTRA, and BIIB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARWR, RVMD, NTRA, and BIIB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARWR, RVMD, NTRA, and BIIB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARWR, RVMD, NTRA, and BIIB Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Biogen NASDAQ:BIIB

Natera NASDAQ:NTRA

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARWR, RVMD, NTRA, and BIIB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARWR, RVMD, NTRA, and BIIB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARWR, RVMD, NTRA, and BIIB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARWR, RVMD, NTRA, and BIIB Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Biogen NASDAQ:BIIB

Natera NASDAQ:NTRA

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools